What the business is
A palm-sized at-home analyzer plus app that measures hormone levels from urine and charts personalized fertility windows, sold direct to consumers.
The bet
Every at-home hormone test, anonymized and pooled, can become a dataset big enough to fill the research void in women's health that inspired the company.
How it started
Sylvia Kang launched Mira in 2017, at the peak of IoT devices and direct-to-consumer products, convinced women deserved better fertility planning than an ovulation test or IVF.
What happened
Kang says early investors only grasped the problem if they had personally lived fertility struggles. By 2024 Mira was tracking and anonymizing every user's results, building the dataset Kang says will 'drive women's health to the new level' (self-reported in the interview).
What has to be true
The device business quietly compounds into a proprietary hormone dataset no clinic can easily replicate.
Anonymized aggregation turns a consumer fertility gadget into infrastructure for medical research.
It explains why a hardware startup could survive investors who didn't get the problem: the asset grows with every test.
Kang's framing — own your results like a doctor visit — pre-empts the privacy question a data pivot invites.
What can be applied
A hardware company's compounding asset can be the data its device generates — provided users trust the anonymization that unlocks it.
Aftermath
As of the September 2024 interview, Mira was actively building the anonymized data layer on top of its device business, with Kang promising it would 'really drive women's health to the new level.' No dataset size, partnerships or revenue figures were disclosed in the interview.
FOLLOW THE EVIDENCE